Category: Joint ventures/collaborations
-
Companies Partner on Implanted Diabetes Beta Cell Device
A company developing implants that release cell therapies is collaborating with a producer of regenerative stem cells to dispense insulin for people with diabetes.
-
Roche, Global Fund to Build Local Diagnostic Processes
The medical products company Roche is partnering with the Global Fund to develop systems and processes for disease diagnostics in low-resource regions.
-
AI-Aided Collaboration to Discover Neuro Disease Drugs
Two biotechnology and health technology companies are discovering precision treatments for neurological disorders with simulation models for individual patients.
-
Virtual Reality Studied for Chronic Cancer Pain
A software company is partnering with a psychologist to explore virtual reality working with mindfulness for relieving pain in cancer patients.
-
Intl. Team Studying Antibiotic Overuse in Pigs
Researchers in Europe and the U.S. are investigating gut processes in pigs to reduce antibiotics commonly used against infections, a source of antibiotic resistance.
-
Partnership Developing Faster, Sensitive Covid-19 Test
A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test.
-
Ginkgo Acquires Bayer Agricultural Biologics Technology
Synthetic biology developer Ginkgo Bioworks is acquiring agricultural biologics assets from Bayer, transforming the companies’ five-year partnership.
-
Cystic Fibrosis Start-Up Raises $111M in New Funds
A developer of new treatments for the inherited lung disease cystic fibrosis emerged from stealth mode, raising $111 million in new venture funds.
-
Synthetic Bio Companies Partner on Therapeutic Microbes
A developer of therapies from engineered microbes is collaborating with a synthetic biology components company on tools to create engineered gut bacteria.
-
Biotech, Synthetic Bio Companies Partner on T-Cell Therapies
A company creating antibodies from synthetic DNA and a developer of engineered T-cells are collaborating on new antibodies to produce T-cell therapeutics.